Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. Here are the 10-highest value M&A … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
December 31, 2019
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: The Fate of Illumina-PacBio Merger Hangs in the Balance
November 30, 2019
Will they or won’t they? The suspense continues over whether Illumina’s proposed rescue of Pacific Biosciences will actually close. The $1.2 billion cash merger, which was originally expected to close … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A roundup of the key mergers, acquisitions, alliances, licenses and other strategic transactions from the past month
October 31, 2019
Although briskness in alliances partially offset sluggishness in M&A, October was far less dynamic than September for strategic deal making within the diagnostics sector. Here’s an overview of the … [Read more...]
INDUSTRY BUZZ
Industry Buzz: Qiagen and the Terrible, Horrible, No Good, Very Bad Day
October 28, 2019
Qiagen has been leaking oil for a while now. But after months of disappointing sales and dashed expectations, things came to a dramatic head over the less than 24 hour period between Oct. 7 and 8, … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
September 30, 2019
After a brief summer lull, strategic deal making ramped up in September, especially in alliance making where volume nearly doubled last month’s levels. Here’s an overview of the long-term trends and … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
August 29, 2019
Big picture-wise, health care industry mergers and acquisitions during the second quarter were up 7.3% from the first quarter and topped 250 deals for the eighth quarter in a row, according to … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
August 5, 2019
The strategic deal making pot continues to boil, despite the relative inactivity of the established market leaders like Quest, LabCorp and Abbott. Here's a look at the trends and major deals from late … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
July 1, 2019
Although not as frantic as the previous month, the pace of deal making remained rapid through the end of May to mid-June. Here's a quick overview of the trends and key deals. Mergers & … [Read more...]
DIAGNOSTIC DEALS
Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month
May 31, 2019
The end of April through mid-May was another busy period for deal making. Here's a quick overview of activity and key deals. Mergers & Acquisitions and Asset Sales Thermo Fisher Scientific's … [Read more...]
